Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. - Wikidata - wikimedia - TriplyDB

Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.

Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.

http://www.wikidata.org/entity/Q36582051

about

Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings How Stigma Surrounding the Use of HIV Preexposure Prophylaxis Undermines Prevention and Pleasure: A Call to Destigmatize "Truvada Whores"Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061 Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064 Personalized Biobehavioral HIV Prevention for Women and Adolescent Girls.Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Preventing HIV infection in women.Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.Topical microbicides and HIV prevention in the female genital tract Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.Perspectives on HIV prevention among urban black women: a potential role for HIV pre-exposure prophylaxis.Linking the population pharmacokinetics of tenofovir and its metabolites with its cellular uptake and metabolism.Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.Preparing for the unexpected: the pivotal role of social and behavioral sciences in trials of biomedical HIV prevention interventions.Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Population pharmacokinetics of tenofovir and tenofovir-diphosphate in healthy women.Summary measures of adherence using pill counts in two HIV prevention trials: the need for standardisation in reporting Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection.Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic review and meta-analysis.How acceptable are antiretrovirals for the prevention of sexually transmitted HIV?: A review of research on the acceptability of oral pre-exposure prophylaxis and treatment as prevention.Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.Effects of partnership change on microbicide gel adherence in a clinical trial (HPTN 035).Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.Methodological lessons from clinical trials and the future of microbicide research.Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial.How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.Acceptability and use of a dapivirine vaginal ring in a phase III trial.Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).Demographic Differences in PrEP-Related Stereotypes: Implications for Implementation.End-Users' Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa.Women and ARV-based prevention: opportunities and challenges.Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa.Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).

P2860

Q26753097-B5F3C110-5FBE-4EC6-8F44-D86A116ADCC0 Q26798250-C6FF7196-4F01-47AD-B127-85F27BF8DD6E Q27005602-8A5DE43E-04E5-4BAC-B02D-48EDE0E9D952 Q27300707-2F1BF218-AD36-4377-91FF-D29E95868413 Q27312940-82758A0C-3022-4683-904B-72CE694D0264 Q27318158-D66D4202-E74E-416F-A088-A71249D8EF26 Q28485356-8DE57D63-2384-4088-A1C5-2EFE0B6D2FAF Q28540042-73949B82-5D50-4FEE-B842-D64108515448 Q28550081-FD9E7F04-9C45-44D7-B853-37BCC91763AF Q30357818-B81C0665-BCC5-4D1A-8AC0-901E234ADD59 Q33765789-8EE8A392-5B47-4B9C-99C4-07C54C5653F6 Q33821090-3AFCAE83-5A30-432E-B5F4-BEFDE083DEE1 Q33855156-8A86A201-2467-43DC-8988-DCE06FF3FCC5 Q33948938-92C48617-04E4-4903-988C-2BDC7BDE20F9 Q34086820-42B5F489-35EA-4BFC-9E4F-2A2E51FAF858 Q34180615-2AE1F2A9-EE8B-4E66-A5B8-7139C57C66A4 Q34606593-4BD139EA-691C-4198-9FC0-C0F46C2CE45B Q34658079-C46BAE0B-ABFA-4D7B-ACCE-40D679B8FE78 Q36952395-844EEE19-7BDF-467E-8038-35309F6813C4 Q37080439-720ADDA0-244F-4775-BE78-3FA8B119AC1B Q37118864-2202D635-7463-44C0-BD5A-FC7BCB100606 Q37210864-632F7752-D484-4985-9B40-58A6428A1C97 Q37224902-E6769B04-49A6-4457-8D34-B9D90E651F29 Q37265920-204FF7F2-66E3-489B-987E-2C871EA4A629 Q37395586-93E6D6BB-DF9C-4729-B90A-A0287DB72E7D Q37395830-4E1FF8C9-80E2-4B37-BBB8-F8EB8B83DD80 Q37526187-081E8447-1BD1-4496-8AFE-EA1C69DE62E2 Q37626085-9F5C9D99-9CCA-405D-89D7-C6E2A197A66C Q37705259-B3A67784-04A0-4AB3-B57C-14B730135D79 Q37736077-4824D93D-E54C-42F3-9FB1-3AD37B10F7C8 Q38062882-62C3A613-965E-4417-AD35-334DE7F01427 Q38616485-7620D5A0-D0E2-44CD-9A5A-82A8F5222825 Q38767384-3435B4D5-2A93-41F0-94C7-22C39A68EEC2 Q38850472-DE126073-483D-498F-AFCC-698B8552A933 Q40465731-5B681E5A-56DB-4A80-8A85-1166AB35F5E5 Q41122508-AD9412D6-F69E-4E95-AC02-A068A077122F Q45980808-62CFBF12-DA8F-4489-ABA3-90DB6163CFAB Q46553256-80B48A49-898A-4693-A4CD-58DCECDC94A7 Q49850256-B7BF69BD-11F9-4DE2-8A5A-BE7AFFAC4C6E Q50028271-C4F7991D-289A-4B47-AFFE-6687F192A378

P2860

Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.

http://www.wikidata.org/entity/Q36582051

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Adherence and acceptability in ...... r for HIV prevention in women.

@ast

Adherence and acceptability in ...... r for HIV prevention in women.

@en

type

label

Adherence and acceptability in ...... r for HIV prevention in women.

@ast

Adherence and acceptability in ...... r for HIV prevention in women.

@en

prefLabel

Adherence and acceptability in ...... r for HIV prevention in women.

@ast

Adherence and acceptability in ...... r for HIV prevention in women.

@en

P1433

Q36582051-EAB528A2-E580-4DFF-9163-B81677B96525

P1476

Q36582051-5D98B1B8-9C24-47B9-9B00-2A362772D204

P2093

Q36582051-240359D7-C74E-41D1-BC9E-C371E4235613

Q36582051-3A13A4D7-854C-424E-B94F-5BF5C4610DD5

Q36582051-3FBF1320-0689-453E-95C0-7EBF85265662

Q36582051-5041E132-D9B6-47B9-9DA4-E8040A8155DA

Q36582051-54739AC2-9BB9-4128-B895-337A7E94D85F

Q36582051-5826D1C6-9EEB-4211-BE83-515597F74BCC

Q36582051-5E977FBC-2726-4557-99C2-19670F69DC7A

Q36582051-69B683D5-A3F5-49D3-A0B2-92CB926F2DDF

Q36582051-6D75B087-2932-4E36-83EE-96C81BA03EAB

Q36582051-8074EA36-4EAC-42A5-9188-CD8A3AC515AB

P2860

Q36582051-04222E63-5404-4F4C-9914-00FD71DFEB09

Q36582051-059DB6BE-E6A9-47A8-96E4-9ABBB6581D1A

Q36582051-0A61B24D-DE83-4F0B-BCD1-1765CF5EF57A

Q36582051-107E714D-E028-4BD7-BC1D-4ABED7819C4B

Q36582051-1DE2894E-5BA7-4432-AF9A-B5C119EE0891

Q36582051-23FA5854-A377-451B-AFC6-4FAA22219785

Q36582051-2C3FCE73-FB4C-4F16-9F2B-A82AE63DE7ED

Q36582051-2F355593-7314-456F-8303-426CF9FD5DBB

Q36582051-2F48CB68-D480-4A9A-A636-BA2872753DCE

Q36582051-4131195D-66A1-4209-AE0B-3543A54E2199

P2888

Q36582051-73D1F04E-D742-45E0-8A32-0DC84E09EFDB

P304

Q36582051-33919384-13D8-4A70-97CF-7ABA23251F04

P31

Q36582051-D665DD7E-BC34-4D96-AAA0-043A267C31C4

P356

Q36582051-FB6AA2B9-0313-4C57-8919-17E1D598783A

P433

Q36582051-D5111249-7D6B-4D37-AF58-721EED6FAF9A

P478

Q36582051-2A52F7D6-78E5-4B8C-849E-69E096390763

P577

Q36582051-3329D9A8-5BDB-4565-9EB3-8F4F3D09389C

P698

Q36582051-2D621FD1-CDA1-4AD3-95AC-99642A3F91C0

P921

Q36582051-6847A9CC-E628-43E4-9CAC-3D580A7CBE63

P932

Q36582051-EECB170F-1B01-4818-B390-101331459A83

P356

S10461-012-0333-8

P1433

AIDS and Behavior

P1476

Adherence and acceptability in ...... r for HIV prevention in women.

@en

P2093

Alexandra M Minnis

http://www.w3.org/2001/XMLSchema#string

Barbra A Richardson

http://www.w3.org/2001/XMLSchema#string

Beatrice A Chen

http://www.w3.org/2001/XMLSchema#string

Clemensia Nakabiito

http://www.w3.org/2001/XMLSchema#string

Craig Hoesley

http://www.w3.org/2001/XMLSchema#string

Craig W Hendrix

http://www.w3.org/2001/XMLSchema#string

Jessica Justman

http://www.w3.org/2001/XMLSchema#string

Kailazarid Gomez

http://www.w3.org/2001/XMLSchema#string

Karen Patterson

http://www.w3.org/2001/XMLSchema#string

Lydia Soto-Torres

http://www.w3.org/2001/XMLSchema#string

P2860

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention.

Expanded safety and acceptability of the candidate vaginal microbicide Carraguard® in South Africa

Intravaginal insertion in KwaZulu-Natal: sexual practices and preferences in the context of microbicide gel use.

Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.

Pre-exposure prophylaxis for HIV prevention: how to predict success.

Randomised controlled trial on whether advance knowledge of prostate-specific antigen testing improves participant reporting of unprotected sex.

Microbicide acceptability research: recent findings and evolution across phases of product development.

P2888

s10461-012-0333-8

P304

737-747

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10461-012-0333-8

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23065145

http://www.w3.org/2001/XMLSchema#string

P921

prevention of HIV/AIDS

P932

3562423

http://www.w3.org/2001/XMLSchema#string